Literature DB >> 7054281

Arming of mononuclear phagocytes by eosinophil peroxidase bound to Staphylococcus aureus.

P G Ramsey, T Martin, E Chi, S J Klebanoff.   

Abstract

When eosinophil peroxidase (EPO) was incubated with Staphylococcus aureus (staph) approximately 40% remained firmly bound to the bacteria as indicated by guaiacol assay. The staph-EPO complex was killed readily by concentrations of H2O2 and a halide that did not alter the viability of control (non-EPO-coated) organisms or organisms pretreated with another basic protein, protamine. This toxic effect was abolished by omitting either H2O2 or halide and was inhibited by azide, cyanide, or aminotriazole. Peroxidase activity was evident on the surface of the organism after ingestion by rabbit blood monocytes. The staph-EPO complex was killed at a greater rate by both rabbit blood monocytes and alveolar macrophages than were control organisms, an effect that did not appear to be secondary to improved phagocytosis. The peroxidase inhibitor azide inhibited the killing of staph-EPO by these mononuclear phagocytes without affecting the killing of control staphylococci; in the presence azide, the killing curve with staph-EPO returned to that seen with control organisms. Further, aerosolized EPO-coated organisms were cleared more rapidly from rat lung than were uncoated organisms or organisms pretreated with protamine. These findings suggest mononuclear phagocytes can utilize EPO bound to the surface of ingested microorganisms to enhance their microbicidal activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7054281

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Acquisition of peroxidase activity by rat alveolar macrophages during pulmonary inflammation.

Authors:  J Shellito; M Sniezek; M Warnock
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

Review 2.  Role of oxidants in microbial pathophysiology.

Authors:  R A Miller; B E Britigan
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

3.  Uptake and utilization of human polymorphonuclear leukocyte granule myeloperoxidase by mouse peritoneal macrophages.

Authors:  K P Leung; M B Goren
Journal:  Cell Tissue Res       Date:  1989-09       Impact factor: 5.249

4.  Macrophage-mediated candidacidal activity is augmented by exposure to eosinophil peroxidase: a paradigm for eosinophil-macrophage interaction.

Authors:  D L Lefkowitz; J A Lincoln; K R Howard; R Stuart; S S Lefkowitz; R C Allen
Journal:  Inflammation       Date:  1997-04       Impact factor: 4.092

5.  Heterogeneity among macrophages cultured from mouse bone marrow. Morphologic, cytochemical and flow cytometric analyses.

Authors:  K P Leung; S W Russell; P A LeBlanc; S Caballero
Journal:  Cell Tissue Res       Date:  1985       Impact factor: 5.249

Review 6.  What really happens in the neutrophil phagosome?

Authors:  James K Hurst
Journal:  Free Radic Biol Med       Date:  2012-05-15       Impact factor: 7.376

7.  Role of high-avidity binding of human neutrophil myeloperoxidase in the killing of Actinobacillus actinomycetemcomitans.

Authors:  K T Miyasaki; J J Zambon; C A Jones; M E Wilson
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

8.  Vesicular uptake of eosinophil peroxidase by guinea pig basophils and by cloned mouse mast cells and granule-containing lymphoid cells.

Authors:  A M Dvorak; S J Klebanoff; W R Henderson; R A Monahan; K Pyne; S J Galli
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

9.  Role for endogenous and acquired peroxidase in the toxoplasmacidal activity of murine and human mononuclear phagocytes.

Authors:  R M Locksley; C B Wilson; S J Klebanoff
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

10.  Comparative study of HOCl-inflicted damage to bacterial DNA ex vivo and within cells.

Authors:  Christine Suquet; Jeffrey J Warren; Nimulrith Seth; James K Hurst
Journal:  Arch Biochem Biophys       Date:  2009-10-20       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.